NCT06571942View on ClinicalTrials.gov

Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

PHASE4RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions
COPD BronchitisPollution Related Respiratory Disorder
Interventions
DRUG

Vilanterol / Umeclidinium (25/62.5 mcg)

One inhalation daily from Ellipta device for three months

DRUG

Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg)

One inhalation daily from Ellipta device for three months

DRUG

Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg

Two inhalations twice daily form pMDI device for three months

DRUG

Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg

Two inhalations twice daily form pMDI device for three months

Trial Locations (1)

14080

RECRUITING

"Insituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas", Mexico City

All Listed Sponsors
lead

National Institute of Respiratory Diseases, Mexico

OTHER_GOV